0.52

5.42% -0.0298

After Hours: .50 -0.02 -3.85%

Pasithea Therapeutics Corp (KTTA)

Overview News Price History Financials Discussions Forecast

Pasithea Therapeutics Corp stock is traded at $0.52, with a volume of 320.07K. It is down -5.42% in the last 24 hours and down -11.11% over the past month. Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Previous Close:

$0.5498

Open:

$0.5333

24h Volume:

320.07K

Relative Volume:

0.35

Market Cap:

$17.38M

Revenue:

Net Income/Loss:

$-19.73M

P/E Ratio:

-0.2507

EPS:

-2.0742

Net Cash Flow:

$-16.94M

1W Performance:

-1.16%

1M Performance:

-11.11%

6M Performance:

-51.85%

1Y Performance:

-28.98%

1-Day Range:

$0.5003

$0.5599

1-Week Range:

$0.47

$0.61

52-Week Range:

$0.281

$2.06

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name

Pasithea Therapeutics Corp

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(702) 514-4174

Address

1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

KTTA's Discussions on Twitter

Compare KTTA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KTTA Pasithea Therapeutics Corp	0.52	17.22M	0	-19.73M	-16.94M	-2.0742
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Pasithea Therapeutics Corp Stock (KTTA) Latest News

Jul 01, 2026

Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan

Jul 01, 2026

Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView

Jul 01, 2026

Jun 30, 2026

Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa

Jun 30, 2026

Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget

Jun 30, 2026

Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com

Jun 30, 2026

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network

Jun 30, 2026

Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens - Stock Titan

Jun 30, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 30, 2026

Jun 29, 2026

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Jun 29, 2026

Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Jun 29, 2026

Jun 26, 2026

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Jun 26, 2026

Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Jun 26, 2026

Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com - Investing.com South Africa

Jun 23, 2026

Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan

Jun 23, 2026